Zoetis shares fell 21.5% after the animal health company reported first-quarter results on May 7, 2026. That drop is now the backdrop to a securities fraud class action in federal court in New York.
The suit is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401, in the U.S. District Court for the Southern District of New York. It covers anyone who bought or otherwise acquired Zoetis (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026. Kessler Topaz Meltzer & Check, a law firm that publicized the case, says investors have until July 27, 2026 to ask the court to appoint them lead plaintiff. The firm notes that it did not file the complaint.
Zoetis makes vaccines, medications and diagnostics for pets and livestock.
The allegations
The complaint says executives made false or misleading statements about the company’s business and prospects during that window, and left out material facts. It names three problems.
First, prescription growth for Librela, a pain treatment for dogs, was weakening after FDA safety warnings about serious neurological complications. Second, Simparica Trio, a flea, tick and heartworm preventative, was losing significant market share to a lower-priced competitor. Third, the dermatology products Apoquel and Cytopoint were also ceding share to competition.
Because of all that, the complaint argues, what the company said about its operations and prospects was materially false and misleading, or lacked a reasonable basis, throughout the class period.
The May results
On May 7, 2026, Zoetis reported first-quarter results that showed a significant decline across its Companion Animal business. The stock fell 21.5% on the news.
How the lead plaintiff role works
A lead plaintiff is a representative who directs the litigation on behalf of the whole class, and is usually the investor or small group with the largest financial interest who is also typical of the class. The lead plaintiff picks the lawyers, subject to court approval. Investors can seek the role, or do nothing and remain absent class members. Their ability to share in any recovery does not depend on which they choose.
The claims are allegations in a complaint and have not been tested in court.
